China’s NMPA approves ViiV Healthcare’s Vocabria in combination with Rekambys for HIV treatment
Betsy Goodfellow | October 26, 2023 | News story | Research and Development | HIV, HIV/AIDS, NMPA, ViiV Healthcare, Vocabria
ViiV Healthcare has announced that the National Medical Products Administration (NMPA) of China has approved Vocabria (cabotegravir injection) used in combination with Janssen’s Rekambys (rilpivirine long-acting injection) for the treatment of human immunodeficiency virus type-1 (HIV-1) infection.
Vocabria is indicated in combination with Rekambys for the treatment of HIV-1 in adult patients who are virologically suppressed and on a stable antiretroviral (ARV) regiment without present or past evidence of viral resistance to, and no prior virological failure with, agents of the non-nucleoside reverse transcriptase inhibitor (NNRTI) and integrase inhibitor (INI) classes.
The drug is approved in tablet form for use alongside Edurant (rilpivirine tablets) as an optional oral lead-in before beginning dosing with the injections or for use as an oral therapy for patients who may miss planned injection doses.
Deborah Waterhouse, CEO of ViiV Healthcare, commented: “At ViiV Healthcare, we are proud to be able to offer innovative solutions that meet the evolving needs of people living with HIV. The approval of cabotegravir injection and rilpivirine long-acting injection marks a step forward in helping to change the treatment experience for some people living with HIV in China who may have challenges with daily HIV therapies. We look forward to working closely with our partners in China to make this treatment available to those who could benefit from a long-acting regimen, part of our commitment to ensuring no person living with HIV is left behind.”
Betsy Goodfellow
Related Content
European Commission approves HIV prevention injection
The European Commission (EC) has granted marketing authorisation for Gilead Science’s Yeytuo (lenacapavir), the first …
HIV vaccine candidate successfully optimised for industrial production
Sumagen Canada Inc, a biotech company based in both South Korea and Canada has partnered …
ViiV Healthcare shares data for two-drug regimen for HIV-1 maintenance therapy
GSK has announced that ViiV Healthcare, a specialist HIV company predominantly owned by GSK with …
